Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial

JACC: Heart Failure

Volumn 5, Issue 4, 2017, Pages 241-252

  Anand, Inder S ^a   Claggett, Brian ^b   Liu, Jiankang ^b   Shah, Amil M ^b   Rector, Thomas S ^a   Shah, Sanjiv J ^c   Desai, Akshay S ^b   O'Meara, Eileen ^d   Fleg, Jerome L ^e   Pfeffer, Marc A ^b   Pitt, Bertram ^f   Solomon, Scott D ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

biomarkers; heart failure; natriuretic peptides; preserved ejection fraction; prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PLACEBO; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEART ARREST; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HOSPITALIZATION; HUMAN; LUNG PRESSURE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SEX; BLOOD; CARDIOVASCULAR DISEASE; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FEMALE; HEART ARREST; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPIRONOLACTONE; STROKE VOLUME;

EID: 85016578062     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.11.015     Document Type: Article

References (23)

1. 1 Cleland, J.G., Taylor, J., Tendera, M., Prognosis in heart failure with a normal ejection fraction. N Engl J Med 357 (2007), 829–830.
2. 2 Anand, I.S., Rector, T.S., Cleland, J.G., et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4 (2011), 569–577.
3. 3 Teerlink, J.R., Metra, M., Felker, G.M., et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373 (2009), 1429–1439.
4. 4 McMurray, J.J., Packer, M., Desai, A.S., et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15 (2013), 1062–1073.
5. 5 Massie, B.M., Carson, P.E., McMurray, J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008), 2456–2467.
6. 6 Solomon, S.D., Zile, M., Pieske, B., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380 (2012), 1387–1395.
7. 7 Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
8. 8 Anjan, V.Y., Loftus, T.M., Burke, M.A., et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol 110 (2012), 870–876.
9. 9 Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131 (2015), 34–42.
10. 10 Shah, A.M., Shah, S.J., Anand, I.S., et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail 7 (2014), 104–115.
11. 11 Armitage, P., Gehan, E.A., Statistical methods for the identification and use of prognostic factors. Int J Cancer 13 (1974), 16–36.
12. 12 Kernan, W.N., Viscoli, C.M., Makuch, R.W., Brass, L.M., Horwitz, R.I., Stratified randomization for clinical trials. J Clin Epidemiol 52 (1999), 19–26.
13. 13 Girerd, N., Ferreira, J., Rossignol, P., Zannad, F., A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. Eur J Heart Fail 18 (2016), 1411–1414.
14. 14 Abhayaratna, W.P., Marwick, T.H., Becker, N.G., Jeffery, I.M., McGill, D.A., Smith, W.T., Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. Am Heart J 152 (2006), 941–948.
15. 15 Iwanaga, Y., Nishi, I., Furuichi, S., et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 47 (2006), 742–748.
16. 16 Grewal, J., McKelvie, R., Lonn, E., et al. BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. Eur J Heart Fail 10 (2008), 252–259.
17. 17 Paulus, W.J., Tschöpe, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62 (2013), 263–271.
18. 18 Zile, M.R., Baicu, C.F., Ikonomidis, J.S., et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 131 (2015), 1247–1259.
19. 19 Solomon, S.D., Claggett, B., Lewis, E.F., et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37 (2016), 455–462.
20. 20 Richards, A.M., Doughty, R., Nicholls, M.G., et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 99 (1999), 786–792.
21. 21 Hartmann, F., Packer, M., Coats, A.J., et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110 (2004), 1780–1786.
22. 22 Anand, I.S., Fisher, L.D., Chiang, Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003), 1278–1283.
23. 23 Zannad, F., Alla, F., Dousset, B., Perez, A., Pitt, B., for the RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102 (2000), 2700–2706.